Trifluoroacetic acid → [3-(5-Amino-3-methyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-phenyl]-(6-bromo-benzo[d]isothiazol-3-yl)-amine
反応式
C(OC(=O)[NH:7][C:8]1[CH2:9][O:10][CH2:11][C:12]([C:15]2[CH:20]=[CH:19][CH:18]=[C:17]([NH:21][C:22]3[C:26]4[CH:27]=[CH:28][C:29]([Br:31])=[CH:30][C:25]=4[S:24][N:23]=3)[CH:16]=2)([CH3:14])[N:13]=1)(C)(C)C.C(O)(C(F)(F)F)=O>C(Cl)Cl>[NH2:7][C:8]1[CH2:9][O:10][CH2:11][C:12]([C:15]2[CH:16]=[C:17]([NH:21][C:22]3[C:26]4[CH:27]=[CH:28][C:29]([Br:31])=[CH:30][C:25]=4[S:24][N:23]=3)[CH:18]=[CH:19][CH:20]=2)([CH3:14])[N:13]=1参加物
4
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
To a solution of {5-[3-(6-Bromo-benzo[d]isothiazol-3-ylamino)-phenyl]-5-methyl-5,6-dihydro-2H-[1,4]oxazin-3-yl}-carbamic acid tert-butyl ester (36 mg, 0.07 mmol) in DCM (1 ml) was added at +5° C. 1 ml TFA. After 20 minutes the mixture was quenched with water and EtOH and evaporated. The residue was taken up in EtOAc/THF and washed with soda, dried with K2CO3 and purified by chromatography on silica gel (DCM/5% MeOH, then DCM/5-10% MeOH containing aq NH3) to yield the title compound.